Cannabis for the Treatment of Epilepsy: an Update
Purpose of Review
For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component of cannabis, in the treatment of epilepsy.
While the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocannabinoid receptors and possible indirect modulation of these receptors via blocking the breakdown of anandamide. Additional targets include activation of the transient receptor potential of vanilloid type-1 (TRPV1), antagonist action at GPR55, targeting of abnormal sodium channels, blocking of T-type calcium channels, modulation of adenosine receptors, modulation of voltage-dependent anion selective channel protein (VDAC1), and modulation of tumor necrosis factor alpha release. We also discuss the most recent studies on various artisanal CBD products conducted in patients with epilepsy in the USA and internationally. While a high percentage of patients in these studies reported improvement in seizures, these studies were either retrospective or conducted via survey. Dosage/preparation of CBD was either unknown or not controlled in the majority of these studies. Finally, we present data from both open-label expanded access programs (EAPs) and randomized placebo-controlled trials (RCTs) of a highly purified oral preparation of CBD, which was recently approved by the FDA in the treatment of epilepsy. In the EAPs, there was a significant improvement in seizure frequency seen in a large number of patients with various types of treatment-refractory epilepsy. The RCTs have shown significant seizure reduction compared to placebo in patients with Dravet syndrome and Lennox-Gastaut syndrome. Finally, we describe the available data on adverse effects and drug-drug interactions with highly purified CBD. While this product is overall well tolerated, the most common side effects are diarrhea and sedation, with sedation being much more common in patients taking concomitant clobazam. There was also an increased incidence of aspartate aminotransferase and alanine aminotransferase elevations while taking CBD, with many of the patients with these abnormalities also taking concomitant valproate. CBD has a clear interaction with clobazam, significantly increasing the levels of its active metabolite N-desmethylclobazam in several studies; this is felt to be due to CBD’s inhibition of CYP2C19. EAP data demonstrate other possible interactions with rufinamide, zonisamide, topiramate, and eslicarbazepine. Additionally, there is one case report demonstrating need for warfarin dose adjustment with concomitant CBD.
Understanding of CBD’s efficacy and safety in the treatment of TRE has expanded significantly in the last few years. Future controlled studies of various ratios of CBD and THC are needed as there could be further therapeutic potential of these compounds for patients with epilepsy.
KeywordsEpilepsy Lennox-Gastaut syndrome Dravet syndrome Cannabis Cannabidiol Tetrahydrocannabinol Interactions Mechanism of action Efficacy
Compliance with Ethical Standards
Conflict of Interest
Dr. Szaflarski reports personal fees from GW Pharmaceuticals; grants and personal fees from Serina Therapeutics, Inc., during the conduct of the study; personal fees from SK Life Sciences; personal fees from LivaNova Inc.; personal fees from Lundbeck; personal fees from NeuroPace Inc.; personal fees from Upsher-Smith Laboratories, Inc.; grants and personal fees from SAGE Pharmaceuticals; grants from UCB Pharma; grants from Biogen; and grants from Eisai Inc., outside the submitted work.
Dr. Gaston reports personal fees from GW Pharmaceuticals, during the conduct of the study.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 13.• Cleeren E, Casteels C, Goffin K, et al. Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. Epilepsia. 2018;59:959–70. This study documents the relationship between epileptogenesis and endocannabinoid system through all stages of epilepsy development. CrossRefPubMedGoogle Scholar
- 14.Szaflarski J. The highs and lows of the endocannabinoid system – Another piece to the epilepsy puzzle? Epilepsy Curr. 2018;in print.Google Scholar
- 24.Rimmerman N, Ben-Hail D, Porat Z, Juknat A, Kozela E, Daniels MP, et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013;4:e949.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.• Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017;70:328–33. While open label, this study discusses various aspects of treating epilepsy with artisanal cannabis products in various settings. CrossRefPubMedGoogle Scholar
- 35.• Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia 2018;59:1540–1548. This open-label study documents the sustained response to cannabidiol over the duration of exposure. CrossRefPubMedGoogle Scholar
- 36.Szaflarski JP, Bebin E, Cutter GR, et al. Cannabidiol improves seizure frequency and severity and reduces adverse events in an open-label prospective study. Epilepsy Behav. 2018; Accepted; In Press.Google Scholar
- 40.McCoy B, Wang L, Zak M, et al. A prospective open-label trial of CBD/THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol. in print.Google Scholar
- 41.Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.Google Scholar
- 47.• Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–96. RCT of cannabidiol for the treatment of seizures associated with Lennox-Gastaut syndrome. CrossRefPubMedGoogle Scholar
- 52.Gaston TE, Liu Y, Cutter GR, Bebin E, Grayson LE, Szaflarski JP. Effect of pharmaceutical formulation of cannabidiol (CBD) on seizure frequency and severity does not appear to be dependent on drug-drug interactions with other anti-epileptic drugs. American Academy of Neurology Annual Meeting; 2018 25 April 2018; Los Angeles, CA.Google Scholar